Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare Treatment With Sirolimus Versus Standard Treatment in Patients Who Have Received a Kidney Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Your child may be eligible for this study if he/she:~* Has received a kidney transplant.~* Has experienced 1 or more episodes of acute rejection or chronic rejection; a rejection episode must have responded to treatment and have occurred at least 30 days before study enrollment.~* Has stable kidney function at the time of study enrollment.~* Is 20 years of age or younger.~* Has written informed consent of parent or guardian if under the age of 18.~* Agrees to use birth control during the study and for 3 months following treatment.~Exclusion Criteria~Your child will not be eligible for this study if he/she:~* Has a history of cancer.~* Has received a multi-organ transplant (more than a kidney).~* Has an active infection.~* Has an abnormal chest X-ray.~* Cannot provide a kidney biopsy at time of study entry.~* Is allergic to sirolimus.~* Has received experimental drugs within 4 weeks of study entry.~* Is pregnant.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive SRL, CsA/tacrolimus, and corticosteroids for up to 36 months
- 2 (Type: EXPERIMENTAL): Participants will receive standard CsA or tacrolimus-based double or triple drug therapy for up to 36 months

Based on this trial design, predict the completion outcome and termination type (if applicable).